Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density.

OBJECTIVE Our purpose was to compare the effects of tibolone, continuous combined hormone replacement therapy, and placebo on mammographic breast density. STUDY DESIGN A prospective, randomized, double-blind placebo-controlled study was performed. A total of 166 postmenopausal women were equally randomized to receive tibolone 2.5 mg, estradiol 2 mg/norethisterone acetate 1 mg (E(2)/NETA), or placebo. Mammograms were performed at baseline and after 6 months of treatment. Mammographic density was quantified according to the Wolfe classification and by the percentage area of the breast that had a dense pattern. RESULTS An increase in mammographic density was much more common among women receiving continuous combined hormone replacement therapy (46%-50%) than among those receiving tibolone (2%-6%) and placebo (0%) treatment. The difference between E(2)/NETA and placebo was highly significant (P <.001). Treatment with tibolone did not differ from that with placebo. The relative risk of an increase in breast density for E(2)/NETA versus tibolone was found to be 8.3 (95% CI 2.7-25.0). CONCLUSION An increase in mammographic density should be regarded as an unwanted side effect of hormone replacement therapy. In contrast to estrogen/progestogen treatment, tibolone seems to exert little stimulation of breast tissue.

[1]  C M Rutter,et al.  Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. , 2001, JAMA.

[2]  B. V. VON Schoultz,et al.  Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens , 2001, Climacteric : the journal of the International Menopause Society.

[3]  R. Ross,et al.  RESPONSE: re: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin , 2000, Journal of the National Cancer Institute.

[4]  R. Hoover,et al.  Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. , 2000, JAMA.

[5]  Dulia Ortega,et al.  Mammographic Density in Postmenopausal Women Treated with Tibolone, Estriol or Conventional Hormone Replacement Therapy , 2000, Clinical drug investigation.

[6]  S. Haslam,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Hormone Replacement Therapy with Estrogen or Estrogen plus Medroxyprogesterone Acetate Is Associated with Increased Epithelial Proliferation , 2022 .

[7]  P. Kenemans,et al.  Hormonal prevention of breast cancer: proposal for a change in paradigm , 1999, British journal of obstetrics and gynaecology.

[8]  B. V. VON Schoultz,et al.  Mammographic breast density during hormone replacement therapy: differences according to treatment. , 1999, American journal of obstetrics and gynecology.

[9]  H. Adami,et al.  Breast‐cancer risk following long‐term oestrogen‐ and oestrogen‐progestin‐replacement therapy , 1999, International journal of cancer.

[10]  G. Chetrite,et al.  Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  Moore Ra.  Livial: a review of clinical studies. , 1999 .

[12]  Linda Olson,et al.  Effects of Estrogen and EstrogenProgestin on Mammographic Parenchymal Density , 1999, Annals of Internal Medicine.

[13]  G. Söderqvist.  Effects of sex steroids on proliferation in normal mammary tissue. , 1998, Annals of medicine.

[14]  N. Boyd,et al.  Mammographic densities and breast cancer risk. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  S. Christau,et al.  A double‐blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms , 1998, British journal of obstetrics and gynaecology.

[16]  J. Rymer.  The effects of tibolone. , 1998, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[17]  G. Ersavasti,et al.  Mammographic changes in women receiving tibolone therapy. , 1998, Fertility and sterility.

[18]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[19]  A. Gompel,et al.  The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells , 1997 .

[20]  L. Skoog,et al.  Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. , 1996, American journal of obstetrics and gynecology.

[21]  D. Macerlaine,et al.  Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. , 1994, AJR. American journal of roentgenology.

[22]  J. Klijn,et al.  Effects of progestagens and Org OD14 in in vitro and in vivo tumor models , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  M. Pike,et al.  Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. , 1994, Journal of the National Cancer Institute.

[24]  J. Wolfe.  Breast patterns as an index of risk for developing breast cancer. , 1976, AJR. American journal of roentgenology.

[25]  J. Wolfe.  Risk for breast cancer development determined by mammographic parenchymal pattern , 1976, Cancer.